Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Moro-Sibilot

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Respiratory Medicine and Research|May 17, 2020
Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST studyC Fontaine-Delaruelle, J Mazières, J Cadranel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trialB Besse, J Mazières, L Ribassin-Majed, et al.
ESMO Open|March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyN Girard, S Galland-Girodet, V Avrillon, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France projectH Blons, J-B Oudart, J-P Merlio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2015
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†J-L Pujol, A Lavole, E Quoix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2019
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trialD Moro-Sibilot, N Cozic, M Pérol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAF<sup>V600</sup> and BRAF<sup>nonV600</sup> mutationsJ Mazieres, C Cropet, L Montané, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialS Peters, J-L Pujol, U Dafni, et al.
ESMO Open|October 16, 2025
Innovative therapeutic cancer vaccine PDC<sup>∗</sup>lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancerJ Vansteenkiste, I Demedts, K Cuppens, et al.
British Journal of Cancer|August 14, 2003
Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000)A Depierre, J L Lagrange, S Theobald, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Respiratory Medicine and Research|May 17, 2020
Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST studyC Fontaine-Delaruelle, J Mazières, J Cadranel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trialB Besse, J Mazières, L Ribassin-Majed, et al.
ESMO Open|March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyN Girard, S Galland-Girodet, V Avrillon, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France projectH Blons, J-B Oudart, J-P Merlio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2015
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†J-L Pujol, A Lavole, E Quoix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2019
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trialD Moro-Sibilot, N Cozic, M Pérol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAF<sup>V600</sup> and BRAF<sup>nonV600</sup> mutationsJ Mazieres, C Cropet, L Montané, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2021
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialS Peters, J-L Pujol, U Dafni, et al.
ESMO Open|October 16, 2025
Innovative therapeutic cancer vaccine PDC<sup>∗</sup>lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancerJ Vansteenkiste, I Demedts, K Cuppens, et al.
British Journal of Cancer|August 14, 2003
Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000)A Depierre, J L Lagrange, S Theobald, et al.
Pageof 8